[11C]carfentanil PET/CT for Healthy Subjects (HS)

Phase-Based Progress Estimates
University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA
Healthy Subjects (HS)
Carfentanil, C-11 - Drug
18 - 65
All Sexes
What conditions do you have?

Study Summary

This study in up to 20 healthy subjects (including 10 females and 10 males) will use [11C]carfentanil whole-body PET imaging to examine the CNS and broader systemic opioid binding and its blockade by the non-selective opioid antagonist naloxone administered parenterally in 2 scan sessions, which can be done the same day or on different days.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Healthy Subjects (HS)

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: Follow up - 1 day to 6 weeks

MOR BPND measurement - [11C]carfentanil
Week 6
MOR BPND measurement - naloxone and [11C]carfentanil

Trial Safety

Safety Progress

1 of 3

Other trials for Healthy Subjects (HS)

Trial Design

1 Treatment Group

[11C]carfentanil PET/CT
1 of 1
Experimental Treatment

20 Total Participants · 1 Treatment Group

Primary Treatment: [11C]carfentanil PET/CT · No Placebo Group · Phase 1

[11C]carfentanil PET/CT
Experimental Group · 1 Intervention: Carfentanil, C-11 · Intervention Types: Drug

Trial Logistics


Participation is compensated

You will be compensated for participating in this trial.

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: follow up - 1 day to 6 weeks
Closest Location: University of Pennsylvania, Perelman School of Medicine · Philadelphia, PA
Photo of Philadelphia  1Photo of Philadelphia  2Photo of Philadelphia  3
2021First Recorded Clinical Trial
1 TrialsResearching Healthy Subjects (HS)
2 CompletedClinical Trials

Eligibility Criteria

Age 18 - 65 · All Participants · 3 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are able to understand and communicate in English.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.